General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0AVEDM
ADC Name
Trastuzumab-Qtag2-MMAE
Synonyms
Trastuzumab-Qtag2-MMAE
   Click to Show/Hide
Organization
Covalab; Centre Léon Bérard; IONTAS Ltd; Institut Curie; PSL Research University.
Drug Status
Investigative
Drug-to-Antibody Ratio
1.5
Antibody Name
Trastuzumab-Qtag2
 Antibody Info 
Antigen Name
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
 Antigen Info 
Payload Name
Monomethyl auristatin E
 Payload Info 
Therapeutic Target
Microtubule (MT)
 Target Info 
Linker Name
PEG4-VC-PAB
 Linker Info 
Conjugate Type
Random conjugation through reduced inter-chain cysteine.
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal inhibitory Concentration (lC50) 
0.363&#1770.02
nM
CVCL_0033
Breast adenocarcinoma
Half Maximal inhibitory Concentration (lC50) 
> 10
nM
CVCL_0179
Invasive breast carcinoma
Half Maximal inhibitory Concentration (lC50) 
> 10
nM
CVCL_0062
Breast adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 0.363&#1770.02 nM Positive HER2 expression (HER2+++/++)
Method Description
In vitro cytotoxicity of CovADC-DM1 and CovADC-MMAE was compared to T-DM1 (Kadcyla, Roche, France) on BT-474 and SKBR3 Her2-positive breast cancer cell lines, MDA-MB-231 Her2-negative cell line was included in the assay to confirm target selectivity. All cell lines were obtained from ATCC and cultured in DMEM supplemented with 10% FBS, 100 U/ml penicillin/streptomycin and 2 mM l-glutamine (Life technologies, France). Cells were maintained at 37 °C with 5% CO2 atmosphere. Optimal cell density of each cell lines was determined by IncuCyte S3 live-cell analysis system (Essence BioScience, UK). Cells were plated (SKBR3 and BT-474: 5000 cells per well, MDA-MB-231: 1,250 cells per well) on 96-well plates. Following the incubation for 24 h, cell culture medium was removed and serial dilutions of ADCs and free unconjugated drugs were added in triplicates. After 3 days incubation cytotoxicity was evaluated by sulforhodamine B assay (SRB assay kit, Sigma, France) based on the measurement of cellular protein content according to the manufacturer's instructions. Briefly, cells were fixed with 50% (wt/vol) TriChloroacetic Acid (TCA) at 4 °C (30 ul/well, final concentration 11.5%) for 1 h. After washing with dH2O cells were stained with 100 ul of 0.04% (wt/vol) SRB solution for 30 min and subsequently washed with 1% (vol/vol) acetic acid to remove unbound stain. Cellular protein bound dye was solubilized in 200 ul of 10 mM Tris base solution (pH 10.5) and the absorption was measured at 510 nm (Microplate reader, Tecan, Switzerland). The raw data was processed using GraphPad Prism 7.0 (GraphPad Software, San Diego, USA). Error bars in graphs represent SEM of two measurements.

   Click to Show/Hide
In Vitro Model Breast adenocarcinoma SK-BR-3 cells CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) > 10 nM Positive HER2 expression (HER2+++/++)
Method Description
In vitro cytotoxicity of CovADC-DM1 and CovADC-MMAE was compared to T-DM1 (Kadcyla, Roche, France) on BT-474 and SKBR3 Her2-positive breast cancer cell lines, MDA-MB-231 Her2-negative cell line was included in the assay to confirm target selectivity. All cell lines were obtained from ATCC and cultured in DMEM supplemented with 10% FBS, 100 U/ml penicillin/streptomycin and 2 mM l-glutamine (Life technologies, France). Cells were maintained at 37 °C with 5% CO2 atmosphere. Optimal cell density of each cell lines was determined by IncuCyte S3 live-cell analysis system (Essence BioScience, UK). Cells were plated (SKBR3 and BT-474: 5000 cells per well, MDA-MB-231: 1,250 cells per well) on 96-well plates. Following the incubation for 24 h, cell culture medium was removed and serial dilutions of ADCs and free unconjugated drugs were added in triplicates. After 3 days incubation cytotoxicity was evaluated by sulforhodamine B assay (SRB assay kit, Sigma, France) based on the measurement of cellular protein content according to the manufacturer's instructions. Briefly, cells were fixed with 50% (wt/vol) TriChloroacetic Acid (TCA) at 4 °C (30 ul/well, final concentration 11.5%) for 1 h. After washing with dH2O cells were stained with 100 ul of 0.04% (wt/vol) SRB solution for 30 min and subsequently washed with 1% (vol/vol) acetic acid to remove unbound stain. Cellular protein bound dye was solubilized in 200 ul of 10 mM Tris base solution (pH 10.5) and the absorption was measured at 510 nm (Microplate reader, Tecan, Switzerland). The raw data was processed using GraphPad Prism 7.0 (GraphPad Software, San Diego, USA). Error bars in graphs represent SEM of two measurements.

   Click to Show/Hide
In Vitro Model Invasive breast carcinoma BT-474 cells CVCL_0179
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) > 10 nM Negative HER2 expression (HER2-)
Method Description
In vitro cytotoxicity of CovADC-DM1 and CovADC-MMAE was compared to T-DM1 (Kadcyla, Roche, France) on BT-474 and SKBR3 Her2-positive breast cancer cell lines, MDA-MB-231 Her2-negative cell line was included in the assay to confirm target selectivity. All cell lines were obtained from ATCC and cultured in DMEM supplemented with 10% FBS, 100 U/ml penicillin/streptomycin and 2 mM l-glutamine (Life technologies, France). Cells were maintained at 37 °C with 5% CO2 atmosphere. Optimal cell density of each cell lines was determined by IncuCyte S3 live-cell analysis system (Essence BioScience, UK). Cells were plated (SKBR3 and BT-474: 5000 cells per well, MDA-MB-231: 1,250 cells per well) on 96-well plates. Following the incubation for 24 h, cell culture medium was removed and serial dilutions of ADCs and free unconjugated drugs were added in triplicates. After 3 days incubation cytotoxicity was evaluated by sulforhodamine B assay (SRB assay kit, Sigma, France) based on the measurement of cellular protein content according to the manufacturer's instructions. Briefly, cells were fixed with 50% (wt/vol) TriChloroacetic Acid (TCA) at 4 °C (30 ul/well, final concentration 11.5%) for 1 h. After washing with dH2O cells were stained with 100 ul of 0.04% (wt/vol) SRB solution for 30 min and subsequently washed with 1% (vol/vol) acetic acid to remove unbound stain. Cellular protein bound dye was solubilized in 200 ul of 10 mM Tris base solution (pH 10.5) and the absorption was measured at 510 nm (Microplate reader, Tecan, Switzerland). The raw data was processed using GraphPad Prism 7.0 (GraphPad Software, San Diego, USA). Error bars in graphs represent SEM of two measurements.

   Click to Show/Hide
In Vitro Model Breast adenocarcinoma MDA-MB-231 cells CVCL_0062
References
Ref 1 Antibody and antibody fragments site-specific conjugation using new Q-tag substrate of bacterial transglutaminase